ArticleInvestigative ophthalmology & visual science2014
Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.
Article in Investigative ophthalmology & visual science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 83 citations in OpenAlex.
- Safety of Long-Acting Intravitreal Hydrogels: A Comprehensive Evaluation of Intraocular Pressure and Retinal Integrity across Rabbit and Non-Human Primate Models.ACS pharmacology & translational science · 2026Review
- Hydrogel-Based Ocular Drug Delivery Systems: A Bibliometric and Visualization Analysis of Research Trends and Hotspots (1991-2025).Pharmaceutics · 2026Article
- Drug-free hyaluronic acid-microneedle with unexpected inhibition activity on benzalkonium chloride-induced corneal inflammation and stromal scarring.Materials today. Bio · 2025Article
- Intraocular drug delivery systems for Diabetic retinopathy: Current and future prospective.BioImpacts : BI · 2025Review
- Review
- Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds.Pharmaceutics · 2023Review
- Ocular Delivery of Therapeutic Proteins: A Review.Pharmaceutics · 2023Review
- Hyaluronic Acid-PEG-Based Diels-AlderBiomacromolecules · 2022Article
- PCL-PEG copolymer based injectable thermosensitive hydrogels.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD).International journal of molecular sciences · 2021Review
- The EyeFlowCell: Development of a 3D-Printed Dissolution Test Setup for Intravitreal Dosage Forms.Pharmaceutics · 2021Article
- Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab.Pharmaceutics · 2021Article
- Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.Pharmaceutics · 2021Review
- Considerations for Polymers Used in Ocular Drug Delivery.Frontiers in medicine · 2021Review
- Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems.Bioengineering (Basel, Switzerland) · 2020Review
- Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices.Frontiers in bioengineering and biotechnology · 2020Review
- A biocompatible reverse thermoresponsive polymer for ocular drug delivery.Drug delivery · 2019Article
- Ocular Drug Delivery: A Special Focus on the Thermosensitive Approach.Nanomaterials (Basel, Switzerland) · 2019Review
- In Situ Cross-linking Hydrogel as a Vehicle for Retinal Progenitor Cell Transplantation.Cell transplantation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeWe assessed the in vivo release profile of bevacizumab from and biocompatibility of poly(ethylene glycol)-poly-(serinol hexamethylene urethane), or ESHU, a thermoresponsive hydrogel administered intravitreally for drug delivery.
methodsThe technical feasibility of injection was assessed quantitatively via mechanical testing. For in vivo studies, New Zealand White rabbit eyes were injected intravitreally with 0.05 mL of either: ESHU dissolved in 25 mg/mL bevacizumab, ESHU dissolved in PBS, or 25 mg/mL bevacizumab. Clinical examination included IOP measurements and examination with indirect ophthalmoscopy for signs of inflammation. Additionally, eyes were examined histologically following euthanasia. To quantify bevacizumab release, aqueous humor samples were obtained via anterior chamber paracentesis and ELISA was used to determine the concentration of drug weekly. In vitro cytotoxicity testing also was performed using bovine corneal endothelial cells.
resultsThe ESHU was injected easily through a 31-gauge needle, was well tolerated in vivo, and caused minimal cell death in vitro when compared to other common materials, such as silicone oil. The long-term presence of the gel did not affect IOP, and there was no evidence of inflammation histologically or through indirect observation. The ESHU sustained the release of bevacizumab for over 9 weeks and maintained a drug concentration that averaged 4.7 times higher than eyes receiving bolus bevacizumab injections.
conclusionsTo our knowledge, this is the first report demonstrating sustained bevacizumab release in vivo from an intravitreally injected hydrogel formulation, suggesting that this delivery system may be a promising candidate for ocular drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.